

STATEMENT

Faes Farma markets bilastine under the brand Bilaxten® in Spain

With great satisfaction we announce that Faes Farma has begun the distribution of the product and thus, from the first week of April, Bilaxten® (bilastine) will be on sale at pharmacies in Spain for the treatment of allergic rhinoconjunctivitis and urticary.

Since 2003 no major advances had been made in the treatment of allergy with antihistamines, so bilastine means a worldwide scientific novelty as well as a milestone for the Spanish pharmaceutical R&D since a pan-European approval was obtained.

Once the technical approval was obtained in September 2010 for 28 European countries, administrative authorizations began in each market, adding 19 so far.

The next step is a price and reimbursement agreement for the product in each country, procedure already completed in Spain. This procedure is of unequal complexity in each territory, so we estimate that bilastine will be launched in the different European countries in the course of the present year.

Internationally, bilastine will be marketed along with first level partners.

Menarini, who will lead the promotion all over Europe, will be co-marketing with GlaxoSmithKline in Spain and Poland, with Pierre Fabre in France and Belgium and with the local leader Vianex in Greece.

Outside Europe, Pfizer will launch the product in Mexico, Nycomed in Brasil, Merck Serono in India, Hikma in the MENA territory and Yuhan in South Korea.

Meanwhile, we continue working to enter into agreements in other important markets, such as Japan, China, Southeast Asia, Central and South America.

Bilastine is a latest generation antihistaminic, with a rapid onset and long lasting action, showing a wide safety profile, indicated for the treatment of allergic rhinoconjunctivitis and urticary.

March 29, 2011.